- NBC Waiting for Brian Williams Apology as Firing Remains Possible
- Fiat Chrysler CEO Marchionne Possibly on Prowl for a Deal With GM
- It's Time for the Eurozone to Let Greece and Tsipras Go
- 'Star Wars' Crushes 'Batman v. Superman' -- and It's Not Even Close
- $15 Minimum Wage Protests Could Spell Major Problem for Retailers
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
New Keytruda data presented for the first time shows an overall response rate of 19% and a median duration of response exceeding one year in lung cancer patients.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
The verdict on an experimental stem cell therapy developed by Athersys to assist the recovery of stroke patients is coming on April 19.